Loading clinical trials...

Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Gasdermin D Expression in Generalized Vitiligo Patients After Narrow-band Ultraviolet B Therapy

NCT06546059•South Valley University

View on ClinicalTrials.gov

Summary

The aim of this study is to: 1. Evaluate the role of tissue Gasdermin D expression using immunehistochemstry techniques in patients with generalized vitiligo and compare it with healthy controls. 2. Evaluation expression of tissue Gasdermin D using immunehistochemstry techniques in patients with generalized vitiligo after narrow band ultraviolet B therapy. 3. Determine whether there is a relationship between Gasdermin D levels and disease duration and involved body surface area (VISA) in vitiligo patients.

Detailed Description

Eligibility

Age

10 - 75 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Patients with stable vitiligo of 6 months duration,
•Both sex and ages(10-75)

Exclusion Criteria

•pregnancy,
•lactation,
•patients under or previous phototherapy,
•patients on other immunosuppressives,
•patients receiving topical or systemic therapy like antioxidants and vitamins were kept off treatment for 2 weeks prior to recruitment into the study.

Key Dates

Start Date

August 1, 2024

Primary Completion Date

October 1, 2024

Completion Date

November 1, 2024

Last Updated

August 9, 2024

Enrollment

ESTIMATED participants

Conditions

Vitiligo, Generalized

Interventions

narrow band ultraviolet-B

DEVICE

Contacts

Soheir Abdel-Hamid, MD

CONTACT

01066877343 soher.abdel-hamid@med.svu.edu.eg

Basma Tito Abd Elhameed, MD

CONTACT

01020304210 Basma.tito@med.svu.edu.eg

Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

NCT07055529

Vitiligo, Generalized

View study

COMPLETEDNA

Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo

NCT04872257

VitiligoVitiligo, Generalized+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 9, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions